This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess benefits and harms of mycophenolate mofetil and enteric‐coated mycophenolate sodium as immunosuppressive agents for liver‐transplanted patients. To assess separately usefulness for achieving current (or improved) targets in anti‐rejection therapy and reducing calcineurin inhibitor side‐effects of mycophenolate mofetil and enteric‐coated mycophenolate sodium as immunosuppressive agents for liver‐transplanted patients.